-
SNS-032: Reading CDK9 Biology Across Cancer Models
2026-10-02
SNS-032 (BMS-387032) is a multi-node CDK inhibitor for dissecting cell-cycle and transcriptional dependencies. This article presents a translational framework for connecting RNA polymerase II phosphorylation, cancer phenotypes, and antiviral assay interpretation without conflating SNS-032 with the distinct CDK9 inhibitor used in recent SARS-CoV-2 research.
-
Tyrothricin for Membrane Research
2026-10-01
Build a membrane-first antimicrobial workflow around Tyrothricin, a peptide antibiotic mixture suited to bacterial, fungal, and carefully controlled exploratory viral studies. This guide translates recent mitochondrial-transfer research into practical assay design, concentration planning, controls, and troubleshooting without overstating cross-domain evidence.
-
Deferiprone Workflows for Iron-Stress Research
2026-10-01
Deferiprone enables controlled iron depletion in cancer biology, enterocyte metabolism, oxidative-stress, and vascular-response models without relying on DMSO or ethanol. This guide translates iron-stress findings into practical dose-finding, repletion, metabolomics, and troubleshooting workflows.
-
PR-619 for Cell-Based DUB Workflows
2026-09-30
PR-619 offers reversible, cell-permeable inhibition of multiple cysteine-dependent deubiquitylating enzymes, enabling ubiquitin accumulation studies without directly blocking proteasomal catalytic activity. This guide turns that distinction into practical workflows for autophagy, cancer biology, and neurodegeneration assays, with controls for solubility, toxicity, and mechanism.
-
NF 449 for Selective P2X1 Platelet Assays
2026-09-30
NF 449 (SKU B6716) provides a practical, evidence-based approach for separating P2X1-driven platelet signaling from broader purinergic and G protein effects. This scenario-based guide covers assay design, controls, formulation, interpretation, and vendor selection without treating NF 449 as a generic cell-viability reagent.
-
GSK126 and the Next Era of EZH2 Biology
2026-09-29
GSK126 is more than a catalytic probe of PRC2: it is a strategic tool for separating EZH2-dependent methylation from noncatalytic chromatin functions. This thought-leadership perspective connects cancer epigenetics research with translational study design, biomarker strategy, and immune-mechanism discovery.
-
Catalpol Rescues Cognition After Sepsis
2026-09-29
A 2024 Journal of Ethnopharmacology study shows that Catalpol reduces LPS-induced post-sepsis cognitive impairment in mice by combining NF-κB-regulated anti-inflammatory activity with TrkB–BDNF neurotrophic signaling. Its integrated behavioral, tissue, pharmacokinetic, and cell-based design provides a useful framework for evaluating compound effects in septic-associated encephalopathy while highlighting important limits of the LPS model.
-
Tomivosertib Reduces Ectopic Activity in Human DRG
2026-09-28
In cultured human dorsal root ganglion neurons obtained during surgery for spinal compression, tomivosertib rapidly and reversibly reduced spontaneous activity, providing direct human-neuron evidence for a role of MNK signaling in neuropathic pain. The electrophysiological changes coincided with loss of eIF4E Ser209 phosphorylation, supporting further study of MNK inhibition while leaving the precise ion-channel mechanism and clinical efficacy unresolved.
-
TPCA-1 and the NF-κB–RIPK1 Decision Point
2026-09-27
TPCA-1 offers a selective way to interrogate IKK-2-dependent NF-κB signaling and inflammatory outputs. Placing that tool alongside recent findings on RIPK1 regulation helps translational researchers distinguish inflammatory transcription from cell-death outcomes—and design experiments that test, rather than assume, how these processes intersect.
-
Heme Oxygenase as a Translational Control Point
2026-09-26
Heme oxygenase links heme turnover to redox and metabolic signaling. Learn how Tin Mesoporphyrin IX (chloride) can help researchers test this biology—and where evidence, assay design, and translational limits matter.
-
Baicalein in Stress-Context Pathway Assays
2026-09-26
Use Baicalein to probe 12-LOX-linked arachidonic acid metabolism, inflammatory signaling, and cancer-cell responses with a workflow that separates target engagement from downstream phenotypes. A recent neurotoxicity study offers a useful model for stress-context assay design—but does not test Baicalein or establish neuroprotective activity for it.
-
Rotigotine Hydrochloride: Mechanism and Research Use
2026-09-25
Rotigotine hydrochloride is a dopamine D2/D3 receptor agonist used in dopaminergic signaling research and as an antiparkinsonian agent. Its transdermal clinical evidence for Parkinson’s disease and restless legs syndrome should be distinguished from preclinical findings on neuroprotection, depression-related behaviors, and bladder function.
-
Polymyxin B: Cleaner Immune–Microbiome Assays
2026-09-25
Polymyxin B is a potent membrane-active antibiotic, but its direct effects on immune cells can complicate microbiome experiments. This article explains how to separate bacterial depletion, host signaling, and treatment effects when designing interpretable assays.
-
CXCR4 Theranostics in Lymphoma: Evidence and Limits
2026-09-24
Dhamecha and colleagues review how CXCR4-targeted PET and SPECT ligands could connect lymphoma characterization with receptor-directed treatment. The article organizes peptide, small-molecule, radioligand, and antibody approaches while emphasizing that physiological CXCR4 expression and compensatory CXCR7 signaling remain important barriers to clinical translation.
-
Doxorubicin Hydrochloride: Assays & Liposome Workflow
2026-09-24
Build reproducible doxorubicin studies from cell-based dose responses to dual-loaded liposome quality checks. This guide pairs practical Doxorubicin hydrochloride assay planning with a recent nPEC study that included doxorubicin-loaded liposomes, while flagging where conditions require local validation.